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Abstract The neuropeptide Y (NPY) receptor Y2 antagonist
BIIE0246 has sub-nanomolar affinity for the human Y2 (hY2)
receptor but binds very poorly to chicken Y2 (chY2) with
micromolar affinity. Sequence comparisons identified several
amino acids for investigation by mutagenesis. Reciprocal
mutagenesis between hY2 and chY2 revealed that three of these,
individually and in combination, are important for BIIE0246
binding, namely positions Gln135 in transmembrane (TM) 3,
Leu227 in TM5, and Leu284 in TM6. Mutagenesis of hY2 to the
corresponding amino in chY2 (generating hY2[Q135H,L227Q,
L284F]) made the affinity of BIIE0246 as low as for chY2.
Introduction into chY2 of the three human residues resulted in
antagonist affinity almost as high as for hY2. To distinguish
between direct and indirect effects, each of the three residues in
hY2 was replaced with alanine. BIIE0246 bound with 28-fold
lower affinity to hY2[L227A], suggesting the Leu227 interacts
directly with the antagonist. The other two alanine mutants
bound with unaltered affinity, suggesting that the corresponding
chY2 residues abolish binding through steric hindrance or charge
repulsion. Thus, three amino acid residues can in an additive
manner completely account for the difference in antagonist
binding between the hY2 and chY2 receptors. These results will
be useful for construction of three-dimensional models of the
widely divergent NPY receptor subtypes. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Neuropeptide Y (NPY) is one of the most abundant neuro-
peptides in the mammalian brain. It forms together with the
hormones peptide YY (PYY) and pancreatic polypeptide (PP)
a family of structurally related 36 amino acid peptides [1].
NPY, PYY, and PP act on a family of G-protein-coupled
receptors: Y1, Y2, Y4, Y5, and y6 [2,3] in£uencing many
important physiological and mental conditions such as
mood, feeding, body temperature, blood pressure and repro-
duction (see [4,5] for reviews). The Y2 receptor [6^8,25,26]
subtype has been shown to mainly be located presynaptically,
regulating the release of neurotransmitter [9]. It has also been
suggested to be involved in NPY’s e¡ect on circadian rhythms
[10].
Interestingly, the NPY receptor subtypes Y1, Y2 and Y5
di¡er greatly from each other and display only 27^32% overall
amino acid identity although all three do respond to the same
peptide ligands NPY and PYY [3,11]. In fact, these receptors
may be the most divergent G-protein-coupled receptors that
bind the same peptide ligand. Y2 receptors in mammals can
be distinguished pharmacologically from Y1, Y4, and Y5 re-
ceptors by a Y2-speci¢c antagonist, BIIE0246 [12]. In addi-
tion, amino-terminally truncated peptides such as NPY18^36
are full agonists at the Y2 receptor, while the a⁄nities for the
Y1 and Y5 receptors decrease with progressive amino-termi-
nal truncation. When amino acids Ile31 and Gln34 in the NPY
molecule are replaced by the corresponding amino acids in
PP, leucine and proline, the resulting ligand [Leu31,Pro34]NPY
does not bind to mammalian Y2 receptors while it is a full
agonist at Y1, Y4, Y5 and y6 receptors.
When the Y2 receptor was cloned from the chicken (ch) [13]
it was found to di¡er in ability to bind several of the subtype-
speci¢c ligands de¢ned in mammals. The Y2-selective antag-
onist BIIE0246 did not bind to the chY2 receptor while the
PP-mimicking peptide p[Leu31,Pro34]NPY did. The chY2 se-
quence is 77% identical to the human (h) Y2 receptor. When
only comparing the transmembrane (TM) regions the identity
is 85%. By aligning the hY2 and chY2 receptors (Fig. 1) it was
possible to identify several amino acid residues that might
help account for the species di¡erence in antagonist binding,
particularly one residue in TM5 (Leu227 of hY2 which is a
glutamine in chicken) and one in TM6 (Leu284 in hY2/Phe288
in chY2). Leu227 and Leu284 are conserved in all mammalian
Y2 receptors but di¡er in chY2. When a three-dimensional
model was generated, it was striking how close the Gln135 in
TM3 of the hY2 receptor was to the amino acids in TM5 and
TM6. This amino acid is a histidine in chY2 and the mutation
hY2[Q135H] was subsequently added to the list of mutants.
Several studies on mutagenesis of the Y1 receptor have been
published [14^21]. It has been proposed that the Y1-selective
antagonist BIBP3226 binds to a pocket between TM4, 5, and
6 of the hY1 receptor and that the binding sites for NPY and
BIBP3226 overlap, but are non-identical [18,19]. The large
sequence di¡erences between NPY receptor subtypes men-
tioned above have hampered the use of this information for
modeling of the Y2 and Y5 receptor subtypes. Furthermore,
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the new three-dimensional model of bovine rhodopsin [22] has
triggered reinterpretation of the published Y1 model. We
present here the ¢rst mutagenesis study of the Y2 receptor
and use the high-resolution structure of bovine rhodopsin
[22] to propose a model for the hY2 receptor.
2. Materials and methods
2.1. Generation of mutants of the hY2 and chY2 receptors
The coding sequences of hY2 and chY2 were transferred to a modi-
¢ed pCEP4 vector (Invitrogen, Groningen, The Netherlands) using
polymerase chain reaction (PCR). In order to detect mutated recep-
tors that do not bind any radioligand, the nine amino acid long
FLAG epitope was inserted at the very carboxy-terminal end of the
receptors. Point mutations were introduced using a two-step PCR
procedure. All constructs were fully sequenced on both strands by
automatic £uorescent dye sequencing using an ABI310 (Perkin El-
mer).
2.2. Transfection and binding
Transient transfections of HEK293-EBNA cells and binding to mu-
tant and wild-type (WT) receptors were performed as previously de-
scribed [13].
2.3. Modeling
Computer modeling of the hY2 and chY2 receptors was performed
using Sybyl 6.4 (Tripos) running on a SiliconGraphics O2 computer.
The recently presented model of bovine rhodopsin [22] was used as a
template.
3. Results
3.1. Generation of mutants of the hY2 and chY2 receptors
The hY2 and chY2 receptor genes were introduced into the
eukaryotic expression vector pCEP4. The following hY2 mu-
tant receptors were generated using a PCR-based method and
inserted into pCEP4: Gln135CHis (hY2[Q135H]) in TM3,
Leu227CGln (hY2[L227Q]) in TM5, and Leu284CPhe
(hY2[L284F]) in TM6. The corresponding (reciprocal) muta-
tions were introduced into the chY2 receptor: chY2[H139Q],
chY2[Q231L], and chY2[F288L]. Furthermore, the double
mutants hY2[L227Q,L284F] and chY2[Q231L,F288L] as
well as the triple mutants with all three single mutations,
hY2[Q135H,L227Q,L284F] and chY2[H139Q,Q231L,F288L],
were also generated.
3.2. Transfection
Each of the constructs was transiently transfected into
HEK293-EBNA cells. Stable cell lines expressing the hY2 re-
ceptor and the triple mutant of the chY2 receptor,
chY2[H139Q,Q231L,F288L], were also established as de-
scribed previously [13].
3.3. Binding
The radioligand 125I-pPYY bound to all of the mutants
with similar a⁄nities and similar Bmax as to the WT Y2 re-
ceptors, as shown by saturation experiments. For hY2,
hY2[Q135H,L227Q,L284F], chY2, and chY2[H139Q,Q231L,
F288L], the a⁄nities (Kd) were 57 þ 9, 42 þ 1, 36 þ 6, and
91 þ 9 pM (n = 3) and the Bmax values were 270 þ 30,
160 þ 30, 190 þ 40, and 190 þ 20 fmol/mg protein, respectively.
Fig. 1. K-Helices 3, 5, and 6 of the hY2 and chY2 receptors com-
pared to bovine rhodopsin. The helices are supposed to pierce the
membrane and were selected based on [22]. Amino acids that are
conserved in all mammalian Y2 receptors (that bind BIIE0246) but
di¡er in the chY2 receptor are shown in bold. Amino acids that dif-
fer among mammalian Y2 are underlined. Arrows point at the three
positions found to a¡ect BIIE0246 binding.
Table 1
Binding of NPY, BIIE0246, and [Leu31,Pro34]NPY to WT and mutant hY2 and chY2
Receptor/mutant NPY BIIE0246 [Leu31,Pro34]NPY
pKi þ S.E.M. vs. hY2 vs. chY2 pKi þ S.E.M. vs. hY2 vs. chY2 pKi þ S.E.M. vs. hY2 vs. chY2
hY2 9.12 þ 0.03 1 1.3 s 9.15 þ 0.08 1 1300u 5.95 þ 0.10 1 76 s
hY2[Q135H] 9.44 þ 0.10 2.1u 1.7u 7.48 þ 0.08 47 s 29u s 5.5 s 3 s s 100 s
hY2[Q135A] 9.08 þ 0.02 1.1 s 1.4u 9.10 þ 0.11 1.1 s 1180u s 5.5 s 3 s s 100 s
hY2[L227Q] 9.22 þ 0.14 1.3u 1.0 7.33 þ 0.09 64 s 21u 6.33 þ 0.09 2.4u 32 s
hY2[L227A] 9.48 þ 0.05 2.3u 1.8u 7.70 þ 0.11 28 s 48u 6.48 þ 0.09 3.3u 23 s
hY2[L284F] 9.24 þ 0.13 1.4u 1.1u 8.34 þ 0.10 6.4 s 210u 6.49 þ 0.07 3.4u 22 s
hY2[L284A] 9.29 þ 0.12 1.5u 1.2u 8.81 þ 0.13 2.1 s 620u 5.98 þ 0.09 1.1u 72 s
hY2[L227Q,L284F] 9.63 þ 0.03 3.3u 2.6u 6.32 þ 0.04 680 s 2u 7.13 þ 0.11 15u 5 s
hY2[Q135H,L227Q,L284F] 9.51 þ 0.07 2.5u 2.0u 5.96 þ 0.10 1530 s 1.1 s 6.11 þ 0.05 1.4u 54 s
chY2 9.24 þ 0.04 1.3u 1 6.02 þ 0.10 1330 s 1 7.83 þ 0.06 76u 1
chY2[H139Q] 9.47 þ 0.08 2.3u 1.8u 7.31 þ 0.07 69 s 19u 7.24 þ 0.08 19u 3.9 s
chY2[Q231L] 9.35 þ 0.06 1.7u 1.4u 6.47 þ 0.07 470 s 2.8u 7.71 þ 0.05 57u 1.3 s
chY2[F288L] 9.32 þ 0.08 1.6u 1.3u 6.38 þ 0.04 590 s 2.2u 6.61 þ 0.06 4.6u 16 s
chY2[Q231L,F288L] 8.81 þ 0.07 2.1 s 2.6 s 6.47 þ 0.07 480 s 2.8u 6.45 þ 0.05 3.1u 24 s
chY2[H139Q,Q231L,F288L] 9.20 þ 0.10 1.2u 1.0 8.74 þ 0.07 2.6 s 520u 6.66 þ 0.06 5.1u 15 s
Inhibition of 125I-pPYY by pNPY, BIIE0246, and [Leu31,Pro34]NPY. Data are presented as pKi þ S.E.M. for three to nine experiments and
compared to the human and chicken WT receptors. Numbers in the second and third column for each ligand indicate X-fold change in a⁄nity
for the mutated receptor and arrows indicate increase (u) or decrease (s) in a⁄nity compared to the WT hY2 (second column) and chY2
(third column) receptors, respectively.
FEBS 25954 26-4-02 Cyaan Magenta Geel Zwart
M.M. Berglund et al./FEBS Letters 518 (2002) 5^96
Furthermore, pNPY displaced 125I-pPYY with similar a⁄n-
ities at all receptor mutants tested (no change was more than
2.5-fold, see Table 1). In contrast, the antagonist BIIE0246
showed decreased a⁄nity for the hY2 receptor mutants
Q135H, L227Q, and L284F by 47-fold, 64-fold, and 6-fold,
respectively. Replacement of all three residues in the same
receptor construct generating hY2[Q135H,L227Q,L284F], re-
duced BIIE0246 a⁄nity to the same level (Ki = 1 WM) as it has
for the WT chY2 receptor (Table 1, Fig. 2). Reciprocal muta-
tions of the corresponding amino acids in the chY2 receptor
generating chY2[H139Q,Q231L,F288L] almost fully restored
BIIE0246 binding (Ki = 2 nM).
When Gln135, Leu227, and Leu284 of the hY2 receptor were
each mutated to alanine, the mutation in TM5, hY2[L227A]
was the only mutation that signi¢cantly a¡ected binding of
BIIE0246 (28-fold decrease). To further explore the impor-
tance of TM5, the mutation hY2[S223M] (located one turn
above Leu227) was made. No signi¢cant e¡ect on BIIE0246 or
NPY binding was found for this mutation (data not shown).
[Leu31,Pro34]NPY did not bind to hY2[Q135H] in the con-
centration range tested (Table 1). At hY2[L227Q] and
hY2[L284F] there were only a 2- and a 3-fold increase in
a⁄nity respectively. When the TM5 and TM6 mutations
were combined in hY2[L227Q,L284F] there was a 15-fold in-
crease in a⁄nity. In the chY2 receptor, [Leu31,Pro34]NPY
bound to the mutant chY2[H139Q] with 3-fold lower a⁄nity
than WT and for chY2[F288L] the e¡ect was 15-fold while
chY2[Q231L] did not a¡ect binding.
4. Discussion
Comparison of receptors across species is a powerful tool to
identify amino acid residues involved in ligand binding, par-
ticularly for synthetic (non-natural) ligands. However, recep-
tor orthologs from di¡erent species of mammals often display
very similar or indistinguishable pharmacological properties
as their sequences are usually highly conserved. In this study
we take advantage of di¡erences between the chY2 receptor as
compared to Y2 in mammals to identify positions important
for antagonist binding.
When the chY2 receptor was cloned, the pharmacological
pro¢le was found to be surprisingly di¡erent from its ortholog
in mammals [13]. The a⁄nity of the Y2 receptor-selective
antagonist BIIE0246 [12] was more than 1000-fold lower for
the chY2 receptor [13] than for the human, rat and guinea pig
Y2 receptors [12,23]. BIIE0246 was designed in a similar way
as the ¢rst hY1 receptor antagonist, BIBP3226 [24], by mod-
i¢cations of the two most carboxy-terminal amino acids of
NPY and PYY, Arg35 and Tyr36. BIBP3226 was found to
interact mainly with amino acids in TM5 and TM6 but also
in TM4 of the hY1 receptor [18]. Assuming that BIIE0246
would interact with the Y2 receptor in a similar manner,
several amino acids of potential interest were identi¢ed in
these regions (Fig. 1). Leu227 in TM5 as well as Leu284 in
TM6 are conserved in all cloned mammalian Y2 receptors
but di¡er in the chY2 receptor where these positions are oc-
cupied by glutamine and phenylalanine, respectively. Interest-
ingly, the position corresponding to Leu227 is also a glutamine
in all known mammalian Y1 and Y5 receptors. In contrast,
Leu284 is conserved in that position of TM6 in all published
and functionally expressed NPY receptors (i.e. both BIIE0246
binding and non-binding) except in chY2. Modeling of the
hY2 receptor based on the recently published structure of
bovine rhodopsin suggested that Gln135 in TM3 is located in
close proximity to Leu227 and Leu284 (11 Aî ), see Fig. 3. The
amino acid that corresponds to Gln135 in the chY2 receptor is
a histidine. This position is more variable between receptor
subtypes than Leu227 and Leu284, as it is a threonine in Y1
and Y4, leucine in Y5 and serine in y6. Based on this infor-
mation the following mutants were made in the hY2 receptor:
hY2[Q135H], hY2[L227Q], and hY2[L284F]. As indicated in
Fig. 2. Binding pro¢les of WT receptors and triple mutants. Com-
parison of pNPY, BIIE0246, and [Leu31,Pro34]NPY in competition
with 125I-pPYY binding to WT and triple mutant hY2 and chY2.
Data are presented as pKi þ S.E.M.
Fig. 3. Model of the hY2 receptor. The hY2 model is based on the X-ray crystallography model of rhodopsin [22]. Left: View from the outside
of the cell (TM1^7). Right: View from the side, inside the membrane (TM3^6). The arrow in the left part indicates the viewing angle in the
right part.
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Table 1, all three mutations reduced antagonist a⁄nity to the
hY2 receptor without changing the a⁄nities of the radioligand
and NPY. When the mutations in TM5 and TM6 were com-
bined in the mutant hY2[L227Q,L284F] the a⁄nity of
BIIE0246 dropped by 680-fold and when all three mutations
were combined the a⁄nity of BIIE0246 was as low as for the
chY2 receptor indicating that these three amino acid replace-
ments are su⁄cient to block antagonist binding (Fig. 2).
To further explore the function of Gln135, Leu227, and
Leu284 in the hY2 receptor, each of these amino acids was
also replaced with alanine. As alanine only bears a minimal
side chain (a methyl group), it is often the amino acid of
choice when studying ‘loss of function’ of a particular amino
acid without a¡ecting the backbone of the protein as glycine
often does. In this case alanine mutations can help determine
whether the amino acids at these positions in hY2 are in-
volved in direct interaction with the antagonist. BIIE0246
bound with higher a⁄nity to all three alanine single mutants
than to the corresponding chicken-resembling mutants. Only
for the TM5 mutation hY2[L227A] was there a signi¢cant
reduction of BIIE0246 a⁄nity compared to the WT receptor
(28-fold). Thus, it is likely that Leu227 in TM5 of the hY2
receptor interacts directly with BIIE0246, possibly with hy-
drophobic parts of the antagonist. The importance of Leu227
is emphasized by the presence of this amino acid in all NPY
receptors that bind BIIE0246 and its absence in all others. In
contrast, it appears that the side chains of His139 in TM3 and
Phe288 in TM6 merely block the docking of the antagonist to
the chY2 receptor. For His139 there may also be a positive
charge that repels the antagonist. The corresponding amino
acid to Leu227 in hY1 (Gln219) has been found to be important
for binding of both NPY and the non-peptide antagonist
BIBP3226 as both lost a⁄nity for hY1 when Gln219 was mu-
tated to alanine [19]. As the structures of BIIE0246 and
BIBP3226 resemble each other, it is reasonable that these
antagonists can interact with amino acids that are in the cor-
responding positions in the mammalian Y1 and Y2 receptors.
To address the question if binding to the chY2 receptor
could be restored by introduction of the human residues at
the three positions discussed above, we made the mutants
chY2[H139Q], chY2[Q231L], and chY2[F288L] and the dou-
ble mutant chY2[Q231L,F288L] as well as the triple mutant
chY2[H139Q,Q231L,F288L]. The mutations in TM5 and
TM6, either alone or combined, improved only marginally
the a⁄nity of BIIE0246 for the chY2 receptor. In contrast,
the mutation in TM3, H139Q, improved the binding of
BIIE0246 considerably but the a⁄nity was still 69-fold lower
than for the hY2 receptor. However, when all three muta-
tions were combined in the triple mutant chY2[H139Q,
Q231L,F288L] the a⁄nity increased dramatically (only 2.6-
fold lower than for the hY2 receptor, Table 1 and Fig. 2).
This agrees with the ¢ndings from the human receptor that
the histidine in TM3 mainly blocks or repels the antagonist
and that the leucine in TM5 is essential for high-a⁄nity bind-
ing of BIIE0246. Thus, reciprocal mutations of the amino
acids in these three positions can almost completely swap
the properties of the hY2 and chY2 receptors with regard to
BIIE0246 binding. The minor remaining di¡erence in a⁄nity
between the human WT receptor and the triple mutant of the
chicken receptor, however, suggests that more subtle and
probably indirect interactions may also be involved.
All three mutations are located about two to three full turns
down in the TM helices from the outer surface of the cell
membrane (Figs. 1 and 3). As none of the mutations a¡ected
NPY or 125I-PYY binding it seems likely that the endogenous
peptide agonists do not reach very far down into the pocket
between the TM regions, but instead have their major sites of
interaction with the outer and external parts of the Y2 recep-
tor. The single mutations had very little e¡ect on the a⁄nity of
the Y2-discriminating (in mammals) peptide [Leu31,Pro34]NPY
while a slight increase in a⁄nity was observed for the double
mutant (15-fold). In line with this, in chY2 the F288L mutant
in TM6 caused [Leu31,Pro34]NPY to lose a⁄nity by about 16-
fold. Although this position harbors a leucine in all other
functionally expressed NPY receptors, even those that allowed
binding of [Leu31,Pro34]NPY, it appears that a phenylalanine
in TM6 is necessary for [Leu31,Pro34]NPY binding to the
chY2 receptor. Thus, this position in TM6 is important
both for BIIE0246 binding to the hY2 receptor and also for
the discrimination against [Leu31,Pro34]NPY, although being
located three turns down in the binding pocket. However, in
contrast to the antagonist, additional amino acid residues, pos-
sibly in the loops, are likely to contribute to [Leu31,Pro34]NPY
binding to the chY2 receptor and/or in discrimination against
binding of this ligand to the hY2 receptor since the hY2 triple
mutant did not allow the a⁄nity displayed for the WT chY2
receptor.
In conclusion, we describe here the ¢rst mutagenesis study
of the Y2 receptor and have identi¢ed three amino acid res-
idues that are important for binding of the Y2-selective an-
tagonist BIIE0246 to the hY2 receptor. We present a model
based on the high-resolution bovine rhodopsin structure that
places these three amino acids in close proximity to one an-
other. Of these three amino acids, Leu227 in TM5 appears to
be the most important in the direct interaction with BIIE0246.
These results will be helpful to generate three-dimensional
models of the widely divergent NPY receptor subtypes Y2
and Y5 as well as improve the Y1 model.
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